S1 BioPharma (Formerly Known As S1 Pharmaceuticals, Inc.)

15 articles about S1 BioPharma (Formerly Known As S1 Pharmaceuticals, Inc.)

• S1 Biopharma CEO Nick Sitchon to Participate in Maxim Group LLC Review of Late Stage Innovations in Women's Health

  3/2/2021

  Sitchon to highlight S1 Biopharma focus on central nervous system role in issues associated with sexual function and sexual wellness.

• S1 Biopharma to Participate in Panel Discussion on Investment Opportunities in China Hosted by Duane Morris and the Chinese Biopharmaceutical Association

  1/4/2019

  S1 Biopharma, Inc. (S1) announced today that the company will participate in a panel discussion, "Innovation Across Borders: Strategies for U.S. and Chinese Companies in the Health Sciences Industry," to be hosted by Duane Morris LLP and the Chinese Biopharmaceutical Association (USA) on Tuesday, January 8, 2019 in San Francisco, CA. The timing of the meeting coincides with the 37th Annual J.P. Morgan Healthcare Conference being held in San Francisco January 7-10, 2019.

• S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys™ for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting

  1/4/2019

  S1 Biopharma, Inc. (S1) announced today that researchers will present an expanded analysis of data from the company's Phase 2a clinical trial of Lorexys™ for the treatment of women with hypoactive sexual desire disorder (HSDD) based on the Patient Global Impression of Change (PGIC) scale

• S1 Biopharma Granted Patents for Lorexys™ in Europe and Asia for Treatment of Hypoactive Sexual Desire Disorder

  12/20/2018

  Newest patents significantly strengthen S1 intellectual property position

• S1 BioPharma (Formerly Known As S1 Pharmaceuticals, Inc.) And Chong Kun Dang Pharmaceutical Corporation Announce Commercialization Agreement For Lorexys In South Korea For Treatment Of Hypoactive Sexual Desire Disorder (HSDD) In Women

  12/8/2015

• Nicolas Sitchon, CEO Of S1 BioPharma (Formerly Known As S1 Pharmaceuticals, Inc.), To Present At BIO-Europe 2015 Conference

  11/2/2015

• Dr. Robert Pyke From S1 BioPharma (Formerly Known As S1 Pharmaceuticals, Inc.) To Present At ExL Pharma CNS Clinical Trial Forum

  11/2/2015

• S1 BioPharma (Formerly Known As S1 Pharmaceuticals, Inc.) Supports FDA Approval Of First-Ever Treatment For Hypoactive Sexual Desire Disorder

  8/20/2015

• S1 BioPharma (Formerly Known As S1 Pharmaceuticals, Inc.) Supports FDA Advisory Committee's Recommendation To Approve The First-Ever Treatment For Hypoactive Sexual Desire Disorder

  6/8/2015

• S1 BioPharma (Formerly Known As S1 Pharmaceuticals, Inc.) Prepares To Initiate Phase 2a Clinical Trial For Low Male Sexual Desire

  3/3/2014

• S1 Pharmaceuticals, Inc. Doses First Patients in Phase 2a Clinical Trial of Lorexys in Premenopausal Women With HSDD

  7/29/2013

• S1 Pharmaceuticals, Inc. Expands Focus to Include Male Sexual Health

  5/14/2012

• S1 Pharmaceuticals, Inc. Announces New Executive Management and Scientific Advisory Board Appointments

  4/24/2012

• S1 Pharmaceuticals, Inc. Announces New Executive Management and Scientific Advisory Board Appointments

  3/8/2012

• S1 Pharmaceuticals, Inc. Announces IND Filing of SIP-104 (Lorexys) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

  2/21/2012